Rain ends stormy year of layoffs by opting to be acquired by Pathos AI over Concentra

14 Dec 2023
·
Deals
www.fiercebiotech.com
Phase 3AcquisitionLicense out/in
The deal would see Rain operate as a subsidiary of Pathos.
After a year of layoffs and declining share prices Pathos wake of a late-stage clinical failure, Rain Oncology’s search for a suitable buyer has paid off.
AI-focused Pathos AI will pay $1.16 per share of Rain, which Pathos described as a 17% premium onRain Oncology price on Oct. 13. In addition, Rain’s shareholders can also expect a contingent value right for up to an additional 17 cents per share depending on the company’s final finances.
The deal, wPathos AIxpected to close in January, has already Pathosoted through by Rain’s board and would see Rain operate as a subsidiary of Pathos. The deal is reliant on Rain having at least $49.6 million on hand in cash and equivalents.
The hurdle should be easy to jump for Rain, which ended September with $77.3 million available. In the same November earnings release that RaiPathoslosed those figures, the company also teased that it would be able to provide an update on its search for “strategic opportunities” by the end of the year.
Boston-based Pathos has developed AI-powered digital pathology tools that have attracted interest from the likes of GSK. In May, the company brought the first clinical-stage drug into its pipeline by securing the license to Novo Nordisk’s CBP/p300 inhibitor program, dubbed FT-7051.
That will now be joined by Rain’s MDM2 inhibitor milademetan. The drug’s failure in a phase 3 trial in liposarcoma earlier this year prompted the biotech to lay off 65% of its workforce in May, plus halt other trials of milaNovo NordiskexpCBP/p300 inhibitorCBP/p300ions that could “enhance” iFT-7051line through a precision oncology acquisition.
“After a thorough assessment, the Rain Board detemilademetan this transaction is in the best interests liposarcomakholders, as it leverages Rain’s strong cash position to provide a confirmed cash takeout for our stockholmilademetantains some future potential upside due to Pathos’ continued interest in further developing milademetan for cancer patients using their proprietary PathOS Platform,” Rain CEO Avanish Vellanki said in a post-market release yesterday.
Pathos wasn’t the only potential suitor circling Rain. The company also received an offer from serial biotech bidder Concentra in October. Rain’s decision to opt for Pathos marks the latest knockback for Tang Capital-owned Concentra, which also failed in its attempts to buPathos Pharmaceuticals. Concentra had better luckmilademetaned a cancerinute offer to snatch Jounce Therapeutics out of the hands of Redx Pharma in March.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.